POG 9201

Phase III Study of Induction With Prednisone, Vincristine, Asparaginase, and Methotrexate, Consolidation With Prednisone, Vincristine, and Methotrexate, and Maintenance With Mercaptopurine, Methotrexate, Prednisone, and Vincristine in Children With Lesser Risk Acute Lymphocytic Leukemia Study: An ALinC #16 Study.

This trial on the cancer.gov site.

Published results.

Treatment for good risk (or lesser risk) B-precursor ALL, no L3 morphology (FAB), defined as:

Date initiated, # of patients:

Protocol Chair:

Specific Aims:

Confirm the treatment results achieved with the least intensive arm of protocol ALinC #14 (POG-8602) in children with lesser risk non-T, non-B acute lymphocytic leukemia.

POG 9201

Back to ALL Trials page

Ped-Onc Resource Center Home


General Disclaimer : These pages are intended for informational purposes only and are not intended to render medical advice. The information provided on Ped Onc Resource Center should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you suspect your child has a health problem, you should consult your health care provider.

Last Updated 4/03

email the editor